Market cap
$0 Mln
Revenue (TTM)
$46 Mln
P/E Ratio
0
P/B Ratio
0.8
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | 14.06 | -19.12 | -9.28 | 12.58 | 1.42 |
| EBIT | 54.04 | 48.25 | 37.64 | -4.09 | 0.07 |
| Net Profit | 56.85 | 42.52 | 33.72 | -15.25 | 2.34 |
| EPS | -- | -- | -- | -- | -- |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-23 | Dec-22 |
| EBIT-Margin
| -43.30 | -46.82 | -34.52 | -36.48 | -52.28 |
| Net Margin
| -- | -54.89 | -41.65 | -- | -- |
| Return on equity
| -390.31 | -361.17 | -- | -888.93 | -190.28 |
| Return on Capital
| -84.07 | -86.49 | -- | -109.74 | -95.13 |
| Return on Assets
| -50.38 | -49.61 | -32.04 | -56.30 | -61.27 |
| Debt to Equity (x)
| -- | -- | -0.03 | -72.51 | 3.08 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
--
|
-109.74
|
-95.13
|
-47.35
|
-80.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
--
|
-888.93
|
-190.28
|
-91.71
|
-323.48
|
|
Peer Median
|
4.94
|
--
|
--
|
--
|
--
|
ROA
-32.04
Lower than Peers by 34.49
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
-32.04
|
-56.30
|
-61.27
|
-33.55
|
-46.19
|
|
Peer Median
|
2.45
|
--
|
--
|
--
|
--
|
EBIT Margin
-34.52
Lower than Peers by 42.99
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
-34.52
|
-36.48
|
-52.28
|
-41.12
|
-62.87
|
|
Peer Median
|
8.47
|
--
|
--
|
--
|
--
|
Net Margin
-41.65
Lower than Peers by 46.32
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
-41.65
|
-41.97
|
-59.09
|
-41.23
|
-62.39
|
|
Peer Median
|
4.68
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-9.28
Lower than Peers by 17.77
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
-9.28
|
0.01
|
0.24
|
0.72
|
-0.40
|
|
Peer Median
|
8.49
|
--
|
--
|
--
|
--
|
EBIT Growth
37.64
Higher than Peers by 26.99
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
37.64
|
29.21
|
-57.22
|
-12.53
|
8.32
|
|
Peer Median
|
10.65
|
--
|
--
|
--
|
--
|
Net Profit Growth
33.72
Higher than Peers by 20.17
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
33.72
|
27.95
|
-77.21
|
3.99
|
5.75
|
|
Peer Median
|
13.55
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-0.03
Lower than Peers by 0.43
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
-0.03
|
-72.51
|
3.08
|
0.60
|
1.79
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-3.28
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
-3.28
|
-12.77
|
0.14
|
0.02
|
0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.71
Lower than Peers by 2.12
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
0.71
|
1.26
|
1.63
|
3.57
|
3.13
|
|
Peer Median
|
2.83
|
--
|
--
|
--
|
--
|
Quick Ratio
0.36
Lower than Peers by 1.69
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
0.36
|
0.68
|
0.73
|
2.63
|
2.13
|
|
Peer Median
|
2.05
|
--
|
--
|
--
|
--
|
Interest Coverage
-6.95
Lower than Peers by 11.91
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
-6.95
|
-7.60
|
-9.22
|
-7.25
|
-6.07
|
|
Peer Median
|
4.96
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
10.50
Lower than Peers by 5.95
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
10.50
|
11.15
|
12.05
|
10.81
|
13.43
|
|
Peer Median
|
16.46
|
--
|
--
|
--
|
--
|
Asset Turnover
0.77
Higher than Peers by 0.27
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
0.77
|
1.34
|
1.04
|
0.81
|
0.63
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
--
|
42.06
|
37.98
|
34.01
|
94.75
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
--
|
153.78
|
161.65
|
194.13
|
243.60
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
--
|
66.72
|
51.03
|
48.04
|
87.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
--
|
129.13
|
148.61
|
180.10
|
250.57
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
0.00
Lower than Peers by 44.46
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
44.46
|
--
|
--
|
--
|
--
|
Price / Book Value
0.77
Lower than Peers by 3.03
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
0.77
|
--
|
--
|
--
|
--
|
|
Peer Median
|
3.79
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.71
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
-0.71
|
-0.75
|
-0.44
|
0.95
|
-0.03
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
0
Lower than Peers by 540
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-23
|
Dec-22
|
Dec-21
|
Dec-20
|
|---|---|---|---|---|---|
|
Biolase (BIOL)
|
0
|
--
|
--
|
--
|
--
|
|
Peer Median
|
540
|
--
|
--
|
--
|
--
|